Robinhood reports August 2025 customer and trading metrics
Semler Scientific, Inc. (NASDAQ:SMLR), a medical technology company with a market capitalization of $416 million and impressive gross profit margins of 91%, reported results of its annual shareholder meeting held Friday, according to a statement filed with the Securities and Exchange Commission. The company’s stock, currently trading at $28.12, has seen a challenging year with a decline of 48% year-to-date, though maintaining a positive 19% return over the past year. According to InvestingPro, the company maintains a GOOD overall financial health score.
Shareholders elected William H.C. Chang as a Class I director to serve until the company’s 2028 annual meeting. Chang received 6,817,708 votes in favor, with 261,303 votes withheld and 2,506,761 broker non-votes.
On an advisory basis, shareholders approved compensation for the company’s named executive officers, with 6,803,887 votes for, 147,170 against, 127,954 abstentions, and 2,506,761 broker non-votes.
Shareholders also approved an amendment to Semler Scientific’s restated certificate of incorporation to increase the number of authorized common shares from 50,000,000 to 210,000,000. The vote was 6,905,107 in favor, 2,209,591 against, and 86,897 abstentions.
A separate proposal to authorize the issuance of 42,000,000 shares of “blank-check” preferred stock did not receive shareholder approval. The results were 4,495,642 votes for, 2,498,626 against, 84,746 abstentions, and 2,506,758 broker non-votes.
Shareholders ratified the selection of BDO USA, P.C. as Semler Scientific’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with 9,551,669 votes for, 17,844 against, and 16,259 abstentions.
All information is based on a press release statement filed with the SEC. Semler Scientific’s common stock is listed on the Nasdaq Stock Market under the symbol SMLR.
In other recent news, Semler Scientific reported an impressive earnings beat for the second quarter of 2025. The company posted earnings per share of $5.04, significantly exceeding the analyst forecast of -$0.22. Revenue also surpassed expectations, reaching $8.22 million compared to the projected $8.1 million. In addition to the earnings report, Cantor Fitzgerald reiterated its Overweight rating on Semler Scientific. However, the firm slightly adjusted its price target from $61.00 to $60.00, noting the recent decline in Bitcoin’s price. Cantor Fitzgerald highlighted that Semler Scientific holds $33.57 worth of Bitcoin per share, indicating that shares are trading near Bitcoin’s net asset value. These developments reflect the company’s strong financial performance and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.